Bardoxolone methyl

Bardoxolone (CDDO; RTA 401) methyl is an orally active and brain-penetrant activator of Nrf2 and an inhibitor of SARS-CoV-2 3CL protease. Bardoxolone methyl inhibits SARS-CoV-2 replication in Vero cells with an EC50 value of 0.29 μM. Bardoxolone methyl increases levels of pNrf2 and HO-1, inhibits inflammatory mediators like pNFκB and MCP-1. Bardoxolone methyl activates the Nrf2 pathway to enhance antioxidant and anti-inflammatory responses, inhibits viral replication, and improves mitochondrial function. Bardoxolone methyl can be used in research on chemotherapy-induced neuropathic pain (CINP), COVID-19, and chronic kidney disease (CKD) [1][2][3][4][5].

Product Specifications

CAS Number

[218600-53-4]

Product Name Alternative

RTA 402; NSC 713200; CDDO Methyl ester

UNSPSC

12352211

Hazard Statement

H302, H315, H319, H335

Target

Keap1-Nrf2; SARS-CoV; Virus Protease

Type

Reference compound

Related Pathways

Anti-infection; NF-κB

Applications

Cancer-programmed cell death

Field of Research

Infection; Inflammation/Immunology; Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/Bardoxolone-methyl.html

Purity

99.66

Solubility

DMSO : 50 mg/mL (ultrasonic)

Smiles

O=C1C(C#N)=C[C@@]2(C)[C@](CC[C@]([C@@]3(C)[C@@]4([H])[C@@]5([H])[C@@](CCC(C)(C)C5)(C(OC)=O)CC3)(C)C2=CC4=O)([H])C1(C)C

Molecular Formula

C32H43NO4

Molecular Weight

505.69

Precautions

H302, H315, H319, H335

References & Citations

[1]Reisman SA, et al. Bardoxolone Methyl Decreases Megalin and Activates Nrf2 in the Kidney. J Am Soc Nephrol. 2012 Aug 2.|[2]McCullough PA, et al. Cardiac and renal function in patients with type 2 diabetes who have chronic kidney disease: potential effects of bardoxolone methyl. Drug Des Devel Ther. 2012;6:141-9.|[3]Yasemin Teksen, et al. Bardoxolone methyl attenuates acetaminophen-induced acute kidney injury by suppressing oxidative stress, inflammation and apoptosis[J]. 2024 May 29;31 (5) :372–379|[4]Kim HK, et al. Bardoxolone Methyl Ameliorates Chemotherapy-Induced Neuropathic Pain by Activation of Phosphorylated Nuclear Factor Erythroid 2-Related Factor 2 in the Dorsal Root Ganglia. Anesth Analg. 2024 Mar 1;138 (3) :664-675.|[5]Sun Q, et al. Bardoxolone and bardoxolone methyl, two Nrf2 activators in clinical trials, inhibit SARS-CoV-2 replication and its 3C-like protease. Signal Transduct Target Ther. 2021 May 29;6 (1) :212.